GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment

Key facts

Sponsor

CHU de Quebec-Universite Laval

Principal Investigator

Lucie Germain, PhD

CHU de Québec-Université Laval

Intervention

Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS)(drug)

Enrollment

9 enrolled

Eligibility

7 years · All sexes

Timeline

2026 – 2035

Study locations (1)

• The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Dystrophic epidermolysis bullosa

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06594393
  A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
  Xinnate AB
• RECRUITINGPHASE1, PHASE2NCT06834035
  Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
  M. Peter Marinkovich
• RECRUITINGPHASE3NCT07016750
  A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
  Krystal Biotech, Inc.
• RECRUITINGPHASE3NCT06917690
  A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
  Chiesi Farmaceutici S.p.A.
• ACTIVE NOT RECRUITINGPHASE3NCT06892639
  Evaluation of D-Fi for the Treatment of Wounds Due to DEB
  Castle Creek Biosciences, LLC.
• RECRUITINGNCT06423573
  A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
  Amryt Pharma
• RECRUITINGPHASE1, PHASE2NCT04173650
  MSC EVs in Dystrophic Epidermolysis Bullosa
  Aegle Therapeutics
• RECRUITINGNCT06563414
  A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
  Krystal Biotech, Inc.

See all trials for Dystrophic epidermolysis bullosa →